CN101299920A - 用选择性雄激素受体调节剂治疗肾病、烧伤、创伤和脊髓损伤 - Google Patents

用选择性雄激素受体调节剂治疗肾病、烧伤、创伤和脊髓损伤 Download PDF

Info

Publication number
CN101299920A
CN101299920A CNA2006800406536A CN200680040653A CN101299920A CN 101299920 A CN101299920 A CN 101299920A CN A2006800406536 A CNA2006800406536 A CN A2006800406536A CN 200680040653 A CN200680040653 A CN 200680040653A CN 101299920 A CN101299920 A CN 101299920A
Authority
CN
China
Prior art keywords
sarm
compound
formula
nhcor
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800406536A
Other languages
English (en)
Chinese (zh)
Inventor
J·T·多尔顿
D·D·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of CN101299920A publication Critical patent/CN101299920A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/32—Tin compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2006800406536A 2005-08-31 2006-08-28 用选择性雄激素受体调节剂治疗肾病、烧伤、创伤和脊髓损伤 Pending CN101299920A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71239005P 2005-08-31 2005-08-31
US60/712,390 2005-08-31

Publications (1)

Publication Number Publication Date
CN101299920A true CN101299920A (zh) 2008-11-05

Family

ID=37809404

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800406536A Pending CN101299920A (zh) 2005-08-31 2006-08-28 用选择性雄激素受体调节剂治疗肾病、烧伤、创伤和脊髓损伤

Country Status (14)

Country Link
US (1) US20070066568A1 (enExample)
EP (2) EP2425715B1 (enExample)
JP (1) JP2009506119A (enExample)
KR (1) KR101388087B1 (enExample)
CN (1) CN101299920A (enExample)
AU (1) AU2006285026B2 (enExample)
BR (1) BRPI0617117A2 (enExample)
CA (1) CA2621189A1 (enExample)
DK (1) DK2425715T3 (enExample)
EA (1) EA200800710A1 (enExample)
ES (1) ES2453981T3 (enExample)
IL (1) IL189843A0 (enExample)
PT (1) PT2425715E (enExample)
WO (1) WO2007027582A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102905526A (zh) * 2010-03-23 2013-01-30 田纳西大学研究基金会 Sarm及其使用方法
CN103002737A (zh) * 2010-01-11 2013-03-27 Gtx公司 治疗睑板腺功能障碍的方法
CN104039767A (zh) * 2011-11-04 2014-09-10 高德美研究及发展公司 N-(吡啶-4-基)酰胺和n-(嘧啶-4-基)酰胺及其药物和化妆品用途
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
JP2006506369A (ja) * 2002-10-15 2006-02-23 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション メチレン架橋選択的アンドロゲン受容体調節剤及びその使用方法
CA2501874A1 (en) * 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
JP5449775B2 (ja) 2005-10-19 2014-03-19 チャバフ ピーティーワイ エルティーディー 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
CN101528214B (zh) 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
WO2009036206A1 (en) * 2007-09-11 2009-03-19 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8377886B2 (en) * 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
JP5604807B2 (ja) * 2008-05-21 2014-10-15 日産自動車株式会社 燃料ホース
ES2614813T3 (es) 2009-04-30 2017-06-02 Midwestern University Nuevos tratamientos terapéuticos usando centaquina
US9511077B2 (en) * 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
US9592243B2 (en) * 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
PL2872482T3 (pl) 2012-07-13 2021-03-08 Oncternal Therapeutics, Inc. Sposób leczenia raków sutka z użyciem selektywnego modulatora receptora androgenowego (sarm)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
KR102138526B1 (ko) * 2014-01-14 2020-07-28 엘지전자 주식회사 퀵 컨트롤 메뉴를 제공하는 디지털 디바이스 및 그 제어 방법
ES2953915T3 (es) 2014-10-22 2023-11-17 Havah Therapeutics Pty Ltd Métodos para reducir la densidad mamaria mamográfica y/o el riesgo de cáncer de mama
SG11201803260PA (en) 2015-10-22 2018-05-30 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
AU2019262612B2 (en) * 2018-05-03 2025-04-03 Midwestern University Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin
CN119970752A (zh) 2019-06-03 2025-05-13 哈瓦赫治疗有限公司 用于递送雄激素剂和芳香酶抑制剂的药物制剂
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
WO2022155543A1 (en) * 2021-01-15 2022-07-21 University Of Tennessee Research Foundation Pharmaceutical compositions for treating breast cancers and methods of uses thereof
US20240293322A1 (en) 2021-06-23 2024-09-05 University Of Iowa Research Foundation Sustained release formulations comprising a selective androgen receptor modulator
WO2025076261A1 (en) * 2023-10-03 2025-04-10 Veru, Inc. Uses of selective androgen receptor modulator (sarm) compounds in chronic weight management

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3865801A (en) 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
ATE122357T1 (de) 1988-01-28 1995-05-15 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
AU628322B2 (en) 1988-01-28 1992-09-17 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
KR100221066B1 (ko) 1989-10-13 1999-10-01 스튜어트 엘.왓트 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5591736A (en) * 1995-07-03 1997-01-07 The Johns Hopkins University Method of retarding the progression of chronic renal failure
US20050038110A1 (en) * 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
CN1149196C (zh) 1998-07-06 2004-05-12 布里斯托尔-迈尔斯斯奎布公司 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
MXPA03001632A (es) * 2000-08-24 2004-09-10 Univ Tennessee Res Corp Moduladores receptores de androgeno selectivos y metodos para usar los mismos.
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
CA2469340A1 (en) * 2001-12-06 2003-06-19 Gtx Inc. Treating muscle wasting with selective androgen receptor modulators
US7803970B2 (en) * 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
WO2003074449A2 (en) * 2002-02-28 2003-09-12 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
EP1558232A4 (en) * 2002-10-15 2008-07-02 Gtx Inc TREATMENT OF FAT SUPPORT WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
AU2003300012A1 (en) * 2002-12-30 2004-07-29 Indiana University Research & Technology Corporation Method of treatment for central nervous system injury
TW200530181A (en) * 2004-01-13 2005-09-16 Bristol Myers Squibb Co Heterocyclic compounds useful as growth hormone secretagogues
US7138389B2 (en) * 2004-02-09 2006-11-21 University Of Washington Oral androgen therapy using modulators of testosterone bioavailability
MXPA06013958A (es) * 2004-06-07 2007-03-15 Univ Tennessee Res Foundation Moduladores del receptor de androgenos selectivo metodos para utilizar los mismos.
CN101528214B (zh) * 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278914B2 (en) 2004-06-07 2016-03-08 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US10300037B2 (en) 2006-08-24 2019-05-28 University Of Tennessee Research Foundation SARMs and method of use thereof
CN103002737A (zh) * 2010-01-11 2013-03-27 Gtx公司 治疗睑板腺功能障碍的方法
CN102905526A (zh) * 2010-03-23 2013-01-30 田纳西大学研究基金会 Sarm及其使用方法
CN104039767A (zh) * 2011-11-04 2014-09-10 高德美研究及发展公司 N-(吡啶-4-基)酰胺和n-(嘧啶-4-基)酰胺及其药物和化妆品用途
JP2014532686A (ja) * 2011-11-04 2014-12-08 ガルデルマ・リサーチ・アンド・デヴェロップメント Ｎ−（ピリド−４−イル）アミドおよびｎ−（ピリミジン−４−イル）アミド、ならびにそれらの医薬的および美容的使用関連出願

Also Published As

Publication number Publication date
ES2453981T3 (es) 2014-04-09
KR20080045726A (ko) 2008-05-23
IL189843A0 (en) 2008-08-07
EP2425715A1 (en) 2012-03-07
JP2009506119A (ja) 2009-02-12
EP2425715B1 (en) 2014-03-05
WO2007027582A2 (en) 2007-03-08
CA2621189A1 (en) 2007-03-08
EA200800710A1 (ru) 2008-06-30
WO2007027582A3 (en) 2007-10-25
DK2425715T3 (da) 2014-04-28
AU2006285026B2 (en) 2012-08-09
BRPI0617117A2 (pt) 2011-07-12
KR101388087B1 (ko) 2014-04-25
US20070066568A1 (en) 2007-03-22
AU2006285026A1 (en) 2007-03-08
PT2425715E (pt) 2014-04-14
EP1931199A4 (en) 2009-07-29
EP1931199A2 (en) 2008-06-18

Similar Documents

Publication Publication Date Title
CN101299920A (zh) 用选择性雄激素受体调节剂治疗肾病、烧伤、创伤和脊髓损伤
KR101068779B1 (ko) 할로겐화된 선택적 안드로겐 수용체 모듈레이터 및 그의사용방법
CN101516840B (zh) 取代的n-酰基苯胺及其应用方法
KR101542812B1 (ko) 당뇨병을 치료하기 위한 선택적인 안드로겐 수용체 모듈레이터
KR100767317B1 (ko) 선택적 안드로겐 수용체 조절자를 이용한 근소모 치료방법
CN1826313B (zh) 选择性雄激素受体调节剂的大规模合成
CN103251579B (zh) 取代的n-酰基苯胺及其使用方法
KR20100014228A (ko) 핵 수용체에 결합하는 물질
MX2008002905A (en) Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
HK1168510A (en) Treating symptoms of renal disease with selective androgen receptor modulators (sarm)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20081105